Home › Endocrine & Clinical › Palopegteriparatide
ClinicalFDA approved

Palopegteriparatide

Also known as: Yorvipath, TransCon PTH

A long-acting prodrug of parathyroid hormone (PTH), FDA-approved as Yorvipath for adults with hypoparathyroidism — the first therapy designed to provide steady, around-the-clock PTH replacement.

Researched & fact-checked by the Peptide Almanac Editorial Team · Last updated

4 cited sources FDA-approved medicine No dosing advice How we research & review →

Quick answer: what is Palopegteriparatide?

Palopegteriparatide (Yorvipath) is the first FDA-approved treatment for hypoparathyroidism in adults.

New to peptides? Start with what are peptides? and how do peptides work?

Quick facts

Class
Long-acting PTH(1-34) prodrug
Brand name
Yorvipath
Approved for
Hypoparathyroidism in adults
Administration
Once-daily subcutaneous injection
Status
FDA-approved (2024), prescription-only
Brand
Yorvipath (Ascendis Pharma)
Approved
FDA, August 2024
Key trial
PaTHway (Phase 3)
Not medical advice. This is an educational summary of an approved prescription medicine. Use only under medical supervision.

Key takeaways

  • It is a long-acting prodrug of parathyroid hormone (PTH) that provides steady, 24-hour hormone replacement from one daily injection.
  • In the Phase 3 PaTHway trial it normalized blood calcium and let most patients stop conventional calcium and active vitamin D.
  • It is a genuine approved prescription peptide drug, distinct from unapproved research compounds.

Overview

Palopegteriparatide is a prodrug of parathyroid hormone (specifically the PTH(1-34) fragment) attached to a carrier that releases the active hormone slowly. This design provides continuous, physiological PTH levels over 24 hours from a single daily injection — a contrast with earlier PTH drugs.[4]

Marketed as Yorvipath by Ascendis Pharma, it was FDA-approved in August 2024 as the first and only treatment for adult hypoparathyroidism, a condition of deficient PTH. It joins the related PTH drugs teriparatide and abaloparatide, but is used for a different purpose.

How it works

Parathyroid hormone regulates calcium and phosphate balance. In hypoparathyroidism the body makes too little PTH, causing low blood calcium that is otherwise managed with high-dose calcium and active vitamin D. Palopegteriparatide replaces the missing hormone: its carrier steadily releases PTH(1-34), restoring calcium handling by the kidney and bone throughout the day.[1][4]

The steady, 24-hour exposure is the key design goal — it aims to normalize calcium while reducing the need for large calcium and vitamin D supplements, and to protect kidney function over the long term.[3]

Clinical evidence

Approval rests on the Phase 3 PaTHway trial. At 26 weeks, palopegteriparatide normalized blood calcium while allowing most participants to stop conventional calcium and active vitamin D therapy.[1] Longer-term (52-week) results confirmed durable calcium control and independence from conventional therapy,[2] and analyses reported improvements in kidney function — an important outcome given the renal risks of long-standing hypoparathyroidism.[3]

Forms & how it's given

Palopegteriparatide is given as a once-daily subcutaneous injection using a prefilled pen, with the dose individualized by a specialist and adjusted alongside monitoring of blood calcium. It is a prescription medicine used under endocrinology supervision; we do not provide dosing protocols.

Safety & status

Common side effects reflect changes in calcium balance and injection-site reactions; as with other PTH therapies, monitoring is central to safe use, and PTH drugs carry class labeling around bone effects. Palopegteriparatide is an FDA-approved, prescription-only medicine — a genuine approved peptide drug, distinct from unapproved research compounds. See also teriparatide and abaloparatide.

Frequently asked questions

What is palopegteriparatide (Yorvipath)?

Palopegteriparatide, sold as Yorvipath, is a long-acting prodrug of parathyroid hormone (PTH). It was FDA-approved in 2024 as the first treatment for adult hypoparathyroidism, providing steady PTH replacement from a once-daily injection.

How is palopegteriparatide different from teriparatide?

Both are PTH-based, but teriparatide is used to build bone in osteoporosis, while palopegteriparatide is a long-acting prodrug designed to replace deficient PTH continuously in hypoparathyroidism. Their purposes and dosing profiles differ.

Is Yorvipath FDA-approved?

Yes. Palopegteriparatide (Yorvipath) received FDA approval in August 2024 for hypoparathyroidism in adults and is a prescription-only medicine used under specialist supervision.

References

Each source links to its original record — peer-reviewed studies, regulator pages, or reference texts, labelled by type. We summarize findings neutrally; a citation is a reference, not an endorsement, and not a claim that its authors reviewed this page.

  1. Khan AA, Rubin MR, Schwarz P, et al. Efficacy and Safety of Parathyroid Hormone Replacement With TransCon PTH in Hypoparathyroidism: 26-Week Results From the Phase 3 PaTHway Trial. J Bone Miner Res. 2023. Peer-reviewed study
  2. Clarke BL, Khan AA, Rubin MR, et al. Efficacy and Safety of TransCon PTH in Adults With Hypoparathyroidism: 52-Week Results From the Phase 3 PaTHway Trial. J Clin Endocrinol Metab. 2025. Peer-reviewed study
  3. Rejnmark L, Gosmanova EO, Khan AA, et al. Palopegteriparatide Treatment Improves Renal Function in Adults with Chronic Hypoparathyroidism: 1-Year Results from the Phase 3 PaTHway Trial. Adv Ther. 2024. Peer-reviewed study
  4. Khan S, Khan AA. Hypoparathyroidism: diagnosis, management and emerging therapies. Nat Rev Endocrinol. 2025. Peer-reviewed study
Related guides: Octreotide · Lanreotide · Pasireotide · All Endocrine & Clinical peptides →

Educational content only — not medical advice. See our Privacy Policy.